



Claims

- 5 1. A compound of formula (I), or a pharmaceutically acceptable salt thereof,




wherein


- 10 X represents N or CH;
R¹ represents



wherein

- 15 R¹⁸ and R²² independently represent hydrogen, halogen, hydroxy or hydroxy-C₁₋₃alkyl-;
R¹⁹ and R²¹ independently represent hydrogen, amino, hydroxy, carboxy, C₁₋₃alkoxy,
amino-C₁₋₃alkyl-, C₁₋₃alkyl-C(=O)-NH-, C₁₋₃alkyl-S(=O)_m-NH- or hydroxy-C₁₋₃alkyl-;
m represents 0, 1 or 2;
R²⁰ represents hydrogen, halogen or C₁₋₃alkoxy; or
R¹ is selected from the group consisting of





wherein

R^{23} represents hydrogen or methyl;

R^{24} represents hydrogen, oxo or C_{1-3} alkyl;

5 $R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}$ and R^{17} independently represent hydrogen or methyl;

or R^2 and R^8 together form an ethylene bridge;

or R^2 and R^6 together form a methylene bridge;

or R^{12} and R^{14} together form an ethylene bridge; and

10 Y represents O, CHR^{25} or $CR^{26}R^{27}$

wherein


R^{25} represents hydroxy or C_{1-3} alkoxy; and


R^{26} and R^{27} independently represent hydrogen or halogen;

with the proviso that the compound of formula (I) is other than 2,6-di-morpholin-4-yl-8-phenyl-

15 9H-purine.

2. A compound of formula (I), or a pharmaceutically acceptable salt thereof,





wherein

R^{18} and R^{22} independently represent hydrogen, halogen, hydroxy or hydroxy- C_{1-3} alkyl-;


R^{19} and R^{21} independently represent hydrogen, amino, hydroxy, carboxy, C_{1-3} alkoxy,

5 amino- C_{1-3} alkyl-, C_{1-3} alkyl- $C(=O)-NH-$, C_{1-3} alkyl- $S(=O)_m-NH-$ or hydroxy- C_{1-3} alkyl-;

m represents 0, 1 or 2;

R^{20} represents hydrogen, halogen or C_{1-3} alkoxy; or

R^1 is selected from the group consisting of



wherein

R^{23} represents hydrogen or methyl;

R^{24} represents hydrogen, oxo or C_{1-3} alkyl;

R^2 , R^3 , R^4 , R^5 , R^6 , R^7 , R^8 , R^9 , R^{10} , R^{11} , R^{12} , R^{13} , R^{14} , R^{15} , R^{16} and R^{17} independently represent

15 hydrogen or methyl; or R^5 and R^6 together form an ethylene bridge; and

Y represents O, CHR^{25} or $CR^{26}R^{27}$

wherein

R^{25} represents hydroxy or C_{1-3} alkoxy; and

R^{26} and R^{27} independently represent hydrogen or halogen;

20 with the proviso that the compound of formula (I) is other than 2,6-di-morpholin-4-yl-8-phenyl-9H-purine.


3. A compound according to Claim 1 or Claim 2, or a pharmaceutically acceptable salt thereof, wherein X represents N.

25

4. A compound according to Claim 1 or Claim 2, or a pharmaceutically acceptable salt thereof, wherein X represents CH.

5. A compound according to any one of Claims 1 to 4, or a pharmaceutically acceptable salt

5 thereof, wherein R¹ represents



wherein

R¹⁸ and R²² independently represent hydrogen, halogen, hydroxy or hydroxy-C₁₋₃alkyl-;

R¹⁹ and R²¹ independently represent hydrogen, amino, hydroxy, carboxy, C₁₋₃alkoxy, amino-C₁₋₃alkyl-, C₁₋₃alkyl-C(=O)-NH-, C₁₋₃alkyl-S(=O)_m-NH- or hydroxy-C₁₋₃alkyl-;


m represents 0, 1 or 2; and

R²⁰ represents hydrogen, halogen or C₁₋₃alkoxy.

6. A compound according to Claim 5, or a pharmaceutically acceptable salt thereof, wherein

at least one of R¹⁸, R¹⁹, R²⁰, R²¹ and R²² is not hydrogen

7. A compound according to any one of Claims 1 to 4, or a pharmaceutically acceptable salt thereof, wherein R¹ is selected from the group consisting of



wherein

R²³ represents hydrogen or methyl; and

R²⁴ represents hydrogen, oxo or C₁₋₃alkyl.

8. A compound according to any one of Claims 1 to 7, or a pharmaceutically acceptable salt thereof, wherein Y represents O;

9. A compound according to any one of Claims 1 to 7, or a pharmaceutically acceptable salt thereof, wherein Y represents CHR^{26} or $\text{CR}^{27}\text{R}^{28}$.

10. A compound according to Claim 1 or Claim 2, which is selected from:

3-[2-((2S,6R)-2,6-Dimethyl-morpholin-4-yl)-6-morpholin-4-yl-9H-purin-8-yl]-phenol;

3-(2,4-dimorpholino-7H-pyrrolo[2,3-d]pyrimidin-6-yl)phenol;

10 2,6-Bis-((S)-3-methyl-morpholin-4-yl)-8-(1H-pyrrolo[2,3-b]pyridin-4-yl)-9H-purine;
{2-Fluoro-5-[6-((S)-3-methyl-morpholin-4-yl)-2-morpholin-4-yl-9H-purin-8-yl]-phenyl}-
methanol;

2-(4,4-Difluoro-piperidin-1-yl)-8-(1H-indol-4-yl)-6-((S)-3-methyl-morpholin-4-yl)-9H-purine;

5-[2,6-Bis-((S)-3-methyl-morpholin-4-yl)-9H-purin-8-yl]-1,3-dihydro-benzimidazol-2-one;

15 {5-[2,6-Bis-((S)-3-methyl-morpholin-4-yl)-9H-purin-8-yl]-2-methoxy-phenyl}-methanol;

8-(1H-Indol-4-yl)-2-morpholin-4-yl-6-(8-oxa-3-aza-bicyclo[3.2.1]oct-3-yl)-9H-purine;

2-Methoxy-5-[6-((S)-3-methyl-morpholin-4-yl)-2-morpholin-4-yl-9H-purin-8-yl]-benzoic acid;

{4-Chloro-3-[6-((S)-3-methyl-morpholin-4-yl)-2-morpholin-4-yl-9H-purin-8-yl]-phenyl}-
methanol;

20 3-(2,6-Di-morpholin-4-yl-9H-purin-8-yl)-benzylamine;

1-{3-[6-((S)-3-Methyl-morpholin-4-yl)-2-morpholin-4-yl-9H-purin-8-yl]-phenyl}-ethanol;

2,6-Di-morpholin-4-yl-8-(1H-pyrrolo[3,2-b]pyridin-6-yl)-9H-purine;

8-(1H-Indol-6-yl)-2,6-bis-((S)-3-methyl-morpholin-4-yl)-9H-purine;

8-(1H-Indol-4-yl)-2,6-bis-((R)-3-methyl-morpholin-4-yl)-9H-purine;

25 1-[8-(1H-Indol-4-yl)-6-((S)-3-methyl-morpholin-4-yl)-9H-purin-2-yl]-piperidin-4-ol;

{3-[2,6-Bis-((S)-3-methyl-morpholin-4-yl)-9H-purin-8-yl]-5-methoxy-phenyl}-methanol;

8-(1H-Indol-4-yl)-2-((R)-3-methyl-morpholin-4-yl)-6-((S)-3-methyl-morpholin-4-yl)-9H-purine;

{3-[2,6-Bis-((R)-3-methyl-morpholin-4-yl)-9H-purin-8-yl]-4-fluoro-phenyl}-methanol;

8-(1H-Indol-4-yl)-6-((R)-3-methyl-morpholin-4-yl)-2-morpholin-4-yl-9H-purine;

30 8-(1H-Indol-6-yl)-6-((R)-3-methyl-morpholin-4-yl)-2-morpholin-4-yl-9H-purine;

8-(1H-Indol-4-yl)-2,6-bis-((S)-3-methyl-morpholin-4-yl)-9H-purine;

8-(1H-Indol-4-yl)-6-((S)-3-methyl-morpholin-4-yl)-2-morpholin-4-yl-9H-purine;

8-(1H-Indol-6-yl)-6-((S)-3-methyl-morpholin-4-yl)-2-morpholin-4-yl-9H-purine;

8-(1H-Indol-4-yl)-2-(4-methoxy-piperidin-1-yl)-6-morpholin-4-yl-9H-purine;

35 8-(1H-Indol-4-yl)-2,6-di-morpholin-4-yl-9H-purine;

- 8-(1H-Indazol-4-yl)-2,6-di-morpholin-4-yl-9H-purine;
8-(1H-Indol-6-yl)-2,6-di-morpholin-4-yl-9H-purine;
3-(2,6-Di-morpholin-4-yl-9H-purin-8-yl)-phenylamine;
N-[3-(2,6-Di-morpholin-4-yl-9H-purin-8-yl)-phenyl]-acetamide;
- 5 8-(2-Methyl-1H-indol-4-yl)-2,6-di-morpholin-4-yl-9H-purine;
3-[2-((2S,6R)-2,6-Dimethyl-morpholin-4-yl)-6-morpholin-4-yl-9H-purin-8-yl]-phenylamine;
N-[3-(2,6-Di-morpholin-4-yl-9H-purin-8-yl)-phenyl]-methanesulfonamide;
{2-[2-((2S,6R)-2,6-Dimethyl-morpholin-4-yl)-6-morpholin-4-yl-9H-purin-8-yl]-phenyl}-
methanol;
- 10 [2-(2,6-Di-morpholin-4-yl-9H-purin-8-yl)-phenyl]-methanol;
3-(2,6-Di-morpholin-4-yl-9H-purin-8-yl)-phenol;
[3-(2,6-Di-morpholin-4-yl-9H-purin-8-yl)-phenyl]-methanol;
2-(2,6-Di-morpholin-4-yl-9H-purin-8-yl)-phenol;
6-(3,3-Dimethyl-morpholin-4-yl)-8-(1H-indol-6-yl)-2-morpholin-4-yl-9H-purine;
- 15 6-(3,3-Dimethyl-morpholin-4-yl)-8-(1H-indol-4-yl)-2-morpholin-4-yl-9H-purine;
8-(2,3-Dihydro-1H-indol-4-yl)-2-((S)-3-methyl-morpholin-4-yl)-6-((R)-3-methyl-morpholin-4-yl)-
9H-purine;
8-(2,3-Dihydro-1H-indol-4-yl)-2,6-bis-((R)-3-methyl-morpholin-4-yl)-9H-purine;
8-(1H-Indol-4-yl)-2-((S)-3-methyl-morpholin-4-yl)-6-((R)-3-methyl-morpholin-4-yl)-9H-purine;
- 20 8-(1H-Indol-6-yl)-2-((S)-3-methyl-morpholin-4-yl)-6-((R)-3-methyl-morpholin-4-yl)-9H-purine;
8-(1H-Indol-6-yl)-2,6-bis-((R)-3-methyl-morpholin-4-yl)-9H-purine;
8-(1H-Indol-4-yl)-6-((R)-3-methyl-morpholin-4-yl)-2-(8-oxa-3-aza-bicyclo[3.2.1]oct-3-yl)-9H-
purine;
8-(1H-Indol-4-yl)-2-((R)-3-methyl-morpholin-4-yl)-6-morpholin-4-yl-9H-purine;
- 25 8-(1H-Indol-6-yl)-2-morpholin-4-yl-6-(1S,4S)-2-oxa-5-aza-bicyclo[2.2.1]hept-5-yl-9H-purine;
8-(1H-Indol-4-yl)-2-((S)-3-methyl-morpholin-4-yl)-6-morpholin-4-yl-9H-purine;
8-(1H-Indol-4-yl)-2-morpholin-4-yl-6-(1S,4S)-2-oxa-5-aza-bicyclo[2.2.1]hept-5-yl-9H-purine;
8-(1H-Indol-6-yl)-6-((S)-3-methyl-morpholin-4-yl)-2-(8-oxa-3-aza-bicyclo[3.2.1]oct-3-yl)-9H-
purine;
- 30 8-(1H-Indol-4-yl)-6-((S)-3-methyl-morpholin-4-yl)-2-(8-oxa-3-aza-bicyclo[3.2.1]oct-3-yl)-9H-
purine;
8-(1H-Indol-6-yl)-2-morpholin-4-yl-6-(3-oxa-8-aza-bicyclo[3.2.1]oct-8-yl)-9H-purine;
8-(1H-Indol-4-yl)-2-morpholin-4-yl-6-(3-oxa-8-aza-bicyclo[3.2.1]oct-8-yl)-9H-purine;
6-(1H-Indol-4-yl)-4-((R)-3-methyl-morpholin-4-yl)-2-((S)-3-methyl-morpholin-4-yl)-7H-
pyrrolo[2,3-d]pyrimidine;
- 35 6-(1H-Indol-4-yl)-2,4-di-morpholin-4-yl-7H-pyrrolo[2,3-d]pyrimidine;

and pharmaceutically acceptable salts thereof.

11. A compound according to any one of Claims 1 to 10, or a pharmaceutically acceptable salt thereof, for use as a medicament.

5

12. A compound according to any one of Claims 1 to 10, or a pharmaceutically acceptable salt thereof, for use in the treatment or prevention of cancer or a neurodegenerative disorder.

10

13. A pharmaceutical composition comprising a compound according to any one of Claims 1 to 10, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient, diluent or carrier

15


14. The use of a compound according to any one of Claims 1 to 10, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment or prevention of cancer or a neurodegenerative disorder.

20

15. A combination comprising a therapeutically effective amount of a compound according to any one of Claims 1 to 10, or a pharmaceutically acceptable salt thereof, and a second drug substance, for simultaneous or sequential administration.

THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:


1. A compound of formula (I), or a pharmaceutically acceptable salt thereof,



wherein

X represents N or CH;

R¹ represents



wherein


R¹⁸ and R²² independently represent hydrogen, halogen, hydroxy or hydroxy-C₁₋₃alkyl-;


R¹⁹ and R²¹ independently represent hydrogen, amino, hydroxy, carboxy, C₁₋₃alkoxy, amino-C₁₋₃alkyl-, C₁₋₃alkyl-C(=O)-NH-, C₁₋₃alkyl-S(=O)_m-NH- or hydroxy-C₁₋₃alkyl-;

m represents 0, 1 or 2;

R²⁰ represents hydrogen, halogen or C₁₋₃alkoxy; or

R¹ is selected from the group consisting of





wherein

R²³ represents hydrogen or methyl;

R²⁴ represents hydrogen, oxo or C₁₋₃alkyl;

R², R³, R⁴, R⁵, R⁶, R⁷, R⁸, R⁹, R¹⁰, R¹¹, R¹², R¹³, R¹⁴, R¹⁵, R¹⁶ and R¹⁷ independently represent hydrogen or methyl;

or R² and R⁸ together form an ethylene bridge;

or R² and R⁶ together form a methylene bridge;

or R¹² and R¹⁴ together form an ethylene bridge; and

Y represents O, CHR²⁵ or CR²⁶R²⁷


wherein

R²⁵ represents hydroxy or C₁₋₃alkoxy; and

R²⁶ and R²⁷ independently represent hydrogen or halogen;

with the proviso that the compound of formula (I) is other than 2,6-di-morpholin-4-yl-8-phenyl-9H-purine.


2. A compound of formula (I), or a pharmaceutically acceptable salt thereof,



wherein

X represents N or CH;

R¹ represents




wherein

R¹⁸ and R²² independently represent hydrogen, halogen, hydroxy or hydroxy-C₁₋₃alkyl-;

R¹⁹ and R²¹ independently represent hydrogen, amino, hydroxy, carboxy, C₁₋₃alkoxy, amino-C₁₋₃alkyl-, C₁₋₃alkyl-C(=O)-NH-, C₁₋₃alkyl-S(=O)_m-NH- or hydroxy-C₁₋₃alkyl-; m represents 0, 1 or 2;

R²⁰ represents hydrogen, halogen or C₁₋₃alkoxy; or

R¹ is selected from the group consisting of



wherein

R²³ represents hydrogen or methyl;

R²⁴ represents hydrogen, oxo or C₁₋₃alkyl;

R², R³, R⁴, R⁵, R⁶, R⁷, R⁸, R⁹, R¹⁰, R¹¹, R¹², R¹³, R¹⁴, R¹⁵, R¹⁶ and R¹⁷ independently represent hydrogen or methyl; or R⁵ and R⁶ together form an ethylene bridge; and

Y represents O, CHR²⁵ or CR²⁶R²⁷

wherein

R²⁵ represents hydroxy or C₁₋₃alkoxy; and


R²⁶ and R²⁷ independently represent hydrogen or halogen;

with the proviso that the compound of formula (I) is other than 2,6-di-morpholin-4-yl-8-phenyl-9H-purine.

3. A compound according to Claim 1 or Claim 2, or a pharmaceutically acceptable salt thereof, wherein X represents N.

4. A compound according to Claim 1 or Claim 2, or a pharmaceutically acceptable salt thereof, wherein X represents CH.

5. A compound according to any one of Claims 1 to 4, or a pharmaceutically acceptable salt thereof, wherein R¹ represents



wherein

R¹⁸ and R²² independently represent hydrogen, halogen, hydroxy or hydroxy-C₁₋₃alkyl-;


R¹⁹ and R²¹ independently represent hydrogen, amino, hydroxy, carboxy, C₁₋₃alkoxy, amino-C₁₋₃alkyl-, C₁₋₃alkyl-C(=O)-NH-, C₁₋₃alkyl-S(=O)_m-NH- or hydroxy-C₁₋₃alkyl-;

m represents 0, 1 or 2; and

R²⁰ represents hydrogen, halogen or C₁₋₃alkoxy.

6. A compound according to Claim 5, or a pharmaceutically acceptable salt thereof, wherein at least one of R¹⁸, R¹⁹, R²⁰, R²¹ and R²² is not hydrogen

7. A compound according to any one of Claims 1 to 4, or a pharmaceutically acceptable salt thereof, wherein R¹ is selected from the group consisting of



wherein

R²³ represents hydrogen or methyl; and

R²⁴ represents hydrogen, oxo or C₁₋₃alkyl.

8. A compound according to any one of Claims 1 to 7, or a pharmaceutically acceptable salt thereof, wherein Y represents O;

9. A compound according to any one of Claims 1 to 7, or a pharmaceutically acceptable salt thereof, wherein Y represents CHR²⁵ or CR²⁶R²⁷.

10. A compound according to Claim 1 or Claim 2, which is selected from:

3-[2-((2S,6R)-2,6-Dimethyl-morpholin-4-yl)-6-morpholin-4-yl-9H-purin-8-yl]-phenol;

3-(2,4-dimorpholino-7H-pyrrolo[2,3-d]pyrimidin-6-yl)phenol;

2,6-Bis-((S)-3-methyl-morpholin-4-yl)-8-(1H-pyrrolo[2,3-b]pyridin-4-yl)-9H-purine;

{2-Fluoro-5-[6-((S)-3-methyl-morpholin-4-yl)-2-morpholin-4-yl-9H-purin-8-yl]-phenyl}-methanol;

2-(4,4-Difluoro-piperidin-1-yl)-8-(1H-indol-4-yl)-6-((S)-3-methyl-morpholin-4-yl)-9H-purine;

5-[2,6-Bis-((S)-3-methyl-morpholin-4-yl)-9H-purin-8-yl]-1,3-dihydro-benzoimidazol-2-one;

{5-[2,6-Bis-((S)-3-methyl-morpholin-4-yl)-9H-purin-8-yl]-2-methoxy-phenyl}-methanol;

8-(1H-Indol-4-yl)-2-morpholin-4-yl-6-(8-oxa-3-aza-bicyclo[3.2.1]oct-3-yl)-9H-purine;

2-Methoxy-5-[6-((S)-3-methyl-morpholin-4-yl)-2-morpholin-4-yl-9H-purin-8-yl]-benzoic acid;

{4-Chloro-3-[6-((S)-3-methyl-morpholin-4-yl)-2-morpholin-4-yl-9H-purin-8-yl]-phenyl}-methanol;

3-(2,6-Di-morpholin-4-yl-9H-purin-8-yl)-benzylamine;

1-{3-[6-((S)-3-Methyl-morpholin-4-yl)-2-morpholin-4-yl-9H-purin-8-yl]-phenyl}-ethanol;

2,6-Di-morpholin-4-yl-8-(1H-pyrrolo[3,2-b]pyridin-6-yl)-9H-purine;

8-(1H-Indol-6-yl)-2,6-bis-((S)-3-methyl-morpholin-4-yl)-9H-purine;

8-(1H-Indol-4-yl)-2,6-bis-((R)-3-methyl-morpholin-4-yl)-9H-purine;

1-[8-(1H-Indol-4-yl)-6-((S)-3-methyl-morpholin-4-yl)-9H-purin-2-yl]-piperidin-4-ol;

{3-[2,6-Bis-((S)-3-methyl-morpholin-4-yl)-9H-purin-8-yl]-5-methoxy-phenyl}-methanol;

8-(1H-Indol-4-yl)-2-((R)-3-methyl-morpholin-4-yl)-6-((S)-3-methyl-morpholin-4-yl)-9H-purine;

{3-[2,6-Bis-((R)-3-methyl-morpholin-4-yl)-9H-purin-8-yl]-4-fluoro-phenyl}-methanol;

8-(1H-Indol-4-yl)-6-((R)-3-methyl-morpholin-4-yl)-2-morpholin-4-yl-9H-purine;
8-(1H-Indol-6-yl)-6-((R)-3-methyl-morpholin-4-yl)-2-morpholin-4-yl-9H-purine;
8-(1H-Indol-4-yl)-2,6-bis-((S)-3-methyl-morpholin-4-yl)-9H-purine;
8-(1H-Indol-4-yl)-6-((S)-3-methyl-morpholin-4-yl)-2-morpholin-4-yl-9H-purine;
8-(1H-Indol-6-yl)-6-((S)-3-methyl-morpholin-4-yl)-2-morpholin-4-yl-9H-purine;
8-(1H-Indol-4-yl)-2-(4-methoxy-piperidin-1-yl)-6-morpholin-4-yl-9H-purine;
8-(1H-Indol-4-yl)-2,6-di-morpholin-4-yl-9H-purine;
8-(1H-Indazol-4-yl)-2,6-di-morpholin-4-yl-9H-purine;
8-(1H-Indol-6-yl)-2,6-di-morpholin-4-yl-9H-purine;
3-(2,6-Di-morpholin-4-yl-9H-purin-8-yl)-phenylamine;
N-[3-(2,6-Di-morpholin-4-yl-9H-purin-8-yl)-phenyl]-acetamide;
8-(2-Methyl-1H-indol-4-yl)-2,6-di-morpholin-4-yl-9H-purine;
3-[2-((2S,6R)-2,6-Dimethyl-morpholin-4-yl)-6-morpholin-4-yl-9H-purin-8-yl]-phenylamine;
N-[3-(2,6-Di-morpholin-4-yl-9H-purin-8-yl)-phenyl]-methanesulfonamide;
{2-[2-((2S,6R)-2,6-Dimethyl-morpholin-4-yl)-6-morpholin-4-yl-9H-purin-8-yl]-phenyl}-
methanol;
[2-(2,6-Di-morpholin-4-yl-9H-purin-8-yl)-phenyl]-methanol;
3-(2,6-Di-morpholin-4-yl-9H-purin-8-yl)-phenol;
[3-(2,6-Di-morpholin-4-yl-9H-purin-8-yl)-phenyl]-methanol;
2-(2,6-Di-morpholin-4-yl-9H-purin-8-yl)-phenol;
6-(3,3-Dimethyl-morpholin-4-yl)-8-(1H-indol-6-yl)-2-morpholin-4-yl-9H-purine;
6-(3,3-Dimethyl-morpholin-4-yl)-8-(1H-indol-4-yl)-2-morpholin-4-yl-9H-purine;
8-(2,3-Dihydro-1H-indol-4-yl)-2-((S)-3-methyl-morpholin-4-yl)-6-((R)-3-methyl-morpholin-4-yl)-9H-purine;
8-(2,3-Dihydro-1H-indol-4-yl)-2,6-bis-((R)-3-methyl-morpholin-4-yl)-9H-purine;
8-(1H-Indol-4-yl)-2-((S)-3-methyl-morpholin-4-yl)-6-((R)-3-methyl-morpholin-4-yl)-9H-purine;
8-(1H-Indol-6-yl)-2-((S)-3-methyl-morpholin-4-yl)-6-((R)-3-methyl-morpholin-4-yl)-9H-purine;
8-(1H-Indol-6-yl)-2,6-bis-((R)-3-methyl-morpholin-4-yl)-9H-purine;
8-(1H-Indol-4-yl)-6-((R)-3-methyl-morpholin-4-yl)-2-(8-oxa-3-aza-bicyclo[3.2.1]oct-3-yl)-9H-purine;
8-(1H-Indol-4-yl)-2-((R)-3-methyl-morpholin-4-yl)-6-morpholin-4-yl-9H-purine;

8-(1H-Indol-6-yl)-2-morpholin-4-yl-6-(1S,4S)-2-oxa-5-aza-bicyclo[2.2.1]hept-5-yl-9H-purine;

8-(1H-Indol-4-yl)-2-((S)-3-methyl-morpholin-4-yl)-6-morpholin-4-yl-9H-purine;

8-(1H-Indol-4-yl)-2-morpholin-4-yl-6-(1S,4S)-2-oxa-5-aza-bicyclo[2.2.1]hept-5-yl-9H-purine;

8-(1H-Indol-6-yl)-6-((S)-3-methyl-morpholin-4-yl)-2-(8-oxa-3-aza-bicyclo[3.2.1]oct-3-yl)-9H-purine;

8-(1H-Indol-4-yl)-6-((S)-3-methyl-morpholin-4-yl)-2-(8-oxa-3-aza-bicyclo[3.2.1]oct-3-yl)-9H-purine;

8-(1H-Indol-6-yl)-2-morpholin-4-yl-6-(3-oxa-8-aza-bicyclo[3.2.1]oct-8-yl)-9H-purine;


8-(1H-Indol-4-yl)-2-morpholin-4-yl-6-(3-oxa-8-aza-bicyclo[3.2.1]oct-8-yl)-9H-purine;

6-(1H-Indol-4-yl)-4-((R)-3-methyl-morpholin-4-yl)-2-((S)-3-methyl-morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidine;

6-(1H-Indol-4-yl)-2,4-di-morpholin-4-yl-7H-pyrrolo[2,3-d]pyrimidine;


and pharmaceutically acceptable salts thereof.

11. A compound which is 8-(1H-Indol-4-yl)-2,6-bis-((R)-3-methyl-morpholin-4-yl)-9H-purine having the following formula:




; or a pharmaceutically acceptable salt thereof.

12. A compound which is 8-(2,3-Dihydro-1H-indol-4-yl)-2-((S)-3-methyl-morpholin-4-yl)-6-((R)-3-methyl-morpholin-4-yl)-9H-purine having the following formula:




; or a pharmaceutically acceptable salt thereof.

13. A compound which is 8-(1H-Indol-4-yl)-2-((S)-3-methyl-morpholin-4-yl)-6-((R)-3-methyl-morpholin-4-yl)-9H-purine having the following formula:



; or a pharmaceutically acceptable salt thereof.

14. A compound which is 8-(1H-Indol-4-yl)-6-((R)-3-methyl-morpholin-4-yl)-2-(8-oxa-3-aza-bicyclo[3.2.1]oct-3-yl)-9H-purine having the following formula:



; or a pharmaceutically acceptable salt thereof.

15. A compound according to any one of Claims 1 to 14, or a pharmaceutically acceptable salt thereof, for use as a medicament.

16. A pharmaceutical composition comprising a compound according to any one of Claims 1 to 14, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient, diluent or carrier.

17. The use of a compound according to any one of Claims 1 to 14, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment or prevention of a neurodegenerative disorder mediated by PI3K and/or mTor.

18. A combination comprising a therapeutically effective amount of a compound according to any one of Claims 1 to 14, or a pharmaceutically acceptable salt thereof, and a second drug substance, for simultaneous or sequential administration.